Speed and Precision: The Lilly and Loxo Partnership

Since the announcement of the record-setting speedy deal acquiring Loxo Oncology earlier this year, Lilly and Loxo haven’t taken their feet off the gas pedal. Speed and precision are key as the partnership strives to build out the precision medicine arm of Lilly Oncology. But the speed doesn’t end there.

As we build our new team, we are simultaneously preparing to bring our first medicine to market. Before the end of 2019, Lilly and Loxo will share with the cancer community pivotal data and file a new drug application with the U.S. Food and Drug administration for a unique medicine designed to target a cancer caused when genes go awry causing uncontrolled cell growth. This fast-paced plan puts the timeline – from first patient receiving treatment to launch – at about 3 years.

Loxo’s focus is on developing medicines for specific patients who don’t yet have treatments available that target the underlying genetics of their cancer, based on a clear understanding of what makes a tumor biology, and their mindset of essentialism. The partnership with Lilly will allow our teams to continue to excel in this distinctive approach to precision oncology.

Lilly Oncology is dedicated to developing and delivering innovative new medicines that will make a meaningful difference to cancer patients. Our research team is leveraging precision medicine and immuno-oncology to bring forth new medicines as fast as possible to help people living with cancer fight their disease. In this case, we plan to launch a new medicine in about half the time it normally takes.

Together, we will continue to identify potential targets that can lead to new medicines and use our collective expertise to resolve any roadblocks that come our way.

The excitement among our team is palpable and the goal is clear, together Lilly and Loxo will speed highly selective, innovative medicines to patients.